Recent Posts
Categories
Blogger and internal medicine-primary care resident Ishani Ganguli posted this ad, created by Britain’s National Health Service, meant to dissuade patients from taking their relatively minor health problems to the emergency room. Read full article >>
NEW YORK (Reuters Health) – Terminally ill cancer patients who watched either of two videos about the option to forego resuscitation overwhelmingly elected that route for the patient in the video, if not for themselves, according to a new study.
NEW YORK (Reuters) – Scientists have discovered yet another way to make a kidney – at least for a rat – that does everything a natural one does, researchers reported on Sunday, a step toward savings thousands of lives and … Continue reading
Ezra Klein and Sarah Kliff discuss why cancer clinics are turning away thousands of Medicare patients. Read full article >>
Cancer clinics across the country have begun turning away thousands of Medicare patients, blaming the sequester budget cuts. Oncologists say the reduced funding, which took effect for Medicare on April 1, makes it impossible to administer expensive chemotherapy drugs while … Continue reading
OKLAHOMA CITY (Reuters) – A Tulsa, Oklahoma, health center on Saturday began drawing blood samples from patients who may have been exposed to viruses at an oral surgery dental clinic that is under investigation.
NEW YORK (Reuters Health) – Patients and their families are rarely told when hospitals make mistakes with their medicines, according to a new study.
NEW YORK (Reuters Health) – Dying cancer patients are less likely to want aggressive end-of-life care if they watch a short video about CPR than if they simply hear about it, according to a new study.
NEW YORK (Reuters Health) – Among people with advanced cancer, poorer patients are less likely to be referred for clinical trials of experimental drugs, a new study from the UK suggests.
ZURICH (Reuters) – Novartis’ Ilaris helps reduce patients’ symptoms and the frequency of attacks in two rare inflammatory diseases, mid-stage studies showed, as the Swiss drugmaker looks to expand the use of the medicine.